GlaxoSmithKline (NYSE: GSK ) reported earnings on Feb. 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), GlaxoSmithKline missed estimates on revenues and whiffed on earnings per share.
Compared to the prior-year quarter, revenue contracted and GAAP earnings per share expanded.
Gross margins dropped, operating margins contracted, net margins improved.
GlaxoSmithKline booked revenue of $10.86 billion. The 12 analysts polled by S&P Capital IQ expected a top line of $11.42 billion. GAAP sales were 3.3% lower than the prior-year quarter's $11.24 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.39. The three earnings estimates compiled by S&P Capital IQ predicted $0.78 per share. GAAP EPS were $0.39 for Q4 against -$0.21 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 72.8%, 150 basis points worse than the prior-year quarter. Operating margin was 26.9%, 2,960 basis points worse than the prior-year quarter. Net margin was 17.9%, 2,750 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $11.01 billion.
Next year's average estimate for revenue is $45.43 billion. The average EPS estimate is $3.52.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 21 members out of 25 rating the stock outperform, and four members rating it underperform. The one CAPS All-Star pick (recommendations by the highest-ranked CAPS members) gives GlaxoSmithKline a green thumbs-up.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on GlaxoSmithKline is outperform, with an average price target of $49.65.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is GlaxoSmithKline the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add GlaxoSmithKline to My Watchlist.